"Holidays" for osteoporosis drugs: A case-based approach.
Title | "Holidays" for osteoporosis drugs: A case-based approach. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Anagnostis, P., Paschou S. A., Kenanidis E., Lambrinoudaki I., Potoupnis M., Tsiridis E., & Goulis D. G. |
Journal | Case Rep Womens Health |
Volume | 23 |
Pagination | e00127 |
Date Published | 2019 Jul |
ISSN | 2214-9112 |
Abstract | •A "drug holiday" can be considered for patients at low fracture risk•It is optimal after completion of five years of alendronate and three years of zoledronic acid or risedronate use•The "drug holiday" strategy should not be implemented for denosumab, estrogen, SERMs or teriparatide. |
DOI | 10.1016/j.crwh.2019.e00127 |
Alternate Journal | Case Rep Womens Health |
PubMed ID | 31431887 |
PubMed Central ID | PMC6580330 |